Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach

Gustavo Obando-Pereda

Proteomics, Inflammation and Pain Laboratory, Universidad Católica de Santa María, Arequipa, Peru

Correspondence
Gustavo Obando-Pereda, Proteomics, Inflammation and Pain Laboratory, Universidad Católica de Santa María, Urb. San José s/n, Umacollo, 04001 Arequipa, Peru. Email: gobando@ucsm.edu.pe

Abstract
PARP14 and PARP9 play a key role in macrophage immune regulation. SARS-CoV-2 is an emerging viral disease that triggers hyper-inflammation known as a cytokine storm. In this study, using in silico tools, we hypothesize about the immunological phenomena of molecular mimicry between SARS-CoV-2 Nsp3 and the human PARP14 and PARP9. The results showed an epitope of SARS-CoV-2 Nsp3 protein that contains consensus sequences for both human PARP14 and PARP9 that are antigens for MHC Classes 1 and 2, which can potentially induce an immune response against human PARP14 and PARP9; while its depletion causes a hyper-inflammatory state in SARS-CoV-2 patients.

KEYWORDS
cytokine storm, macrophage, molecular mimicry, SARS-CoV-2

1 INTRODUCTION

SARS-COV-2 was described in December 2019 as being the result of zoonotic transmission from wild animals traded in the Wuhan market to humans presenting primarily symptoms such as fever, non-productive cough, and myalgia or fatigue, normal or decreased leukocyte counts, and radiographic evidence of pneumonia. On January 7, 2020, the World Health Organization named this virus New Coronavirus 2019 (2019-nCoV). However, the genome of this virus has an 86.9% similarity with the Severe Acute Respiratory Syndrome-Cov (SARS-CoV) genome, and researchers changed the initial name to Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). In a year, by March 21, 2021, this new disease produced a pandemic with 122.524 million cases and over 2.7 million deaths worldwide.

The SARS-CoV-2 is an enveloped positive-sense RNA virus belonging to the Coronaviridae, genus Betacoronavirus family. The SARS-CoV-2 genome contains 14 open reading frames (ORFs), 4 encoded structural proteins, spikes (S), a membrane (M), an envelope (E), and a nucleocapsid (N) that constitute a protective shell surrounding the genetic material. Other remaining proteins, such as the Nsp1-16 and 9 other accessory proteins enhance its virulence. The nonstructural protein 3 (Nsp3) is an important protein for the virus to process viral polyproteins and build a fully functional complex allowing viral propagation. Another function of the Nsp3 is its significant role in regulating the host’s inflammatory and immune response. Several studies demonstrate that the Nsp3 and the human poly-adenosine diphosphate-ribose polymerase 9 (parp9) have identical residues that could produce molecular mimicry, leading to leukopenia and an altered inflammatory response. This condition can be explained by a cytokine storm state, related to the macrophage activation syndrome (MAS).

The PARPs are a family of important enzymes that catalyze post-translational ribosylation modification of proteins using NAD+ as a substrate to carry out mono or poly ADP-riboseylation modification on target proteins to trigger many processes of cellular metabolism, such as DNA repair, regulation of disease pathogenesis, modulation of immune response and is involved in viral infections. Seventeen PARP family members have been described, the most important in immune
regulation being PARP14 and PARP9. PARP14 increases IL-4 induced cytokine through STAT6, responsible for anti-inflammatory macrophage activation (M2), immune homeostasis, tissue injury and inflammatory macrophage regeneration and regulation (M1). PARP9 as PARP14 is responsible for macrophage activation. In the SARS-COV-2 disease, a molecular mimicry phenomenon has been observed, and two recent studies have reported this phenomenon between viral proteins against PARP9 and PARP14. The aim of this study is to analyze the molecular mimicry phenomena using in silico tools between SARS-CoV-2 and human proteins.

2 | METHODS

2.1 | Basic local alignment search tool

The selected Sars-Cov-2 protein sequences: Nsp2 (YP_009742609.1), Nsp3 (YP_009742610.1), Nsp4 (YP_009742611.1), Nsp6 (YP_009742613.1), Nsp7 (YP_009742614.1), Nsp8 (YP_009742615.1), Nsp9 (YP_009742616.1), Nsp10 (YP_009742617.1), Nsp11 (YP_009725312.1), Orf1ab (YP_009724389.1), Orf1a (YP_009725295.1), Orf3 (YP_009724391.1), Orf6 (YP_009724394.1), Orf7a (YP_009724395.1), Orf7b (YP_009725318.1), Orf8 (YP_009724396.1), Orf10 (YP_009725255.1), S (YP_009724390.1), E (YP_009724392.1), M (YP_009724393.1), and N (YP_009724397.2); were submitted to the BLASTp tool, and a sequence similarity search was performed in the human proteome database. Subsequently, a second individual sequence analysis was performed using the BLASTp tool, and a sequence similarity search was performed in the human proteome database. Subsequently, a second individual sequence analysis was performed using the DNASTAR Lasergene software for similar proteins. Sequence alignment was performed using the Clustal Omega server with default parameters.

2.2 | Prediction of B cell, cytotoxic T lymphocytes, and helper T lymphocytes epitopes

The B-cell epitopes were predicted using the BepiPred server and the Elliprot server to examine the epitope position in a 3D structure. The predicted epitope PTVVVN AANVYLKHGGGVAGAL of Nsp3 was extracted from PDB (3Q6Z and 6WEY, respectively).

2.3 | Hydrophobic and antigenic protein analysis

The hydrophobic and antigenic analysis was performed using the Kyte–Doolittle and Jameson–Wolf algorithms of human and viral protein. To determine whether the epitope found was located on the outer surface of the protein where antigen–antibody formation occurs, an overlay of the predicted epitopes and the results of hydrophobic and antigenic analysis was performed. The DNASTAR Protein program was used for this method.

2.4 | Protein modeling and molecular docking

The three-dimensional modeling of PARP9 was performed using the I-TASSER online server (https://zhanglab.ccmb.med.umich.edu/I-TASSER/), while the Z-score was used to verify the quality of the 3D protein modeling to select the best model. Human PARP14 and Sars-CoV-2 Nsp3 were extracted from PDB (3Q6Z and 6WEY, respectively).

In addition, the 3D structure of the selected epitopes was modeled with the PEPFOLD 3 server. Molecular docking of the peptides was performed using the DOCKTOPE server (http://tools.iedb.org/docktope/) for the HLA-A*02:01 allele of MHC Class I and the CABS-dock server (http://212.87.3.12/CABSdock/) for the HLA-DR52 allele of MHC Class II (PBD: 3C5J). The HawKRank server was used for scoring.

3 | RESULTS

3.1 | Basic local alignment search tool

Protein basic local alignment search tool (BLAST) analysis showed the presence of a consensus sequence of fourteen amino acids that can be found in the Nsp3 protein, the ORF1a and ORF1ab of SARS-CoV-2 and in human Parp14 and Parp9, corresponding to amino acid positions Nsp3 (236–260), ORF1ab, and ORF 1a (1054–1078), 818–840 and 113–134 for human PARP14 and PARP9 respectively (Table 1 and Figure 1).

3.2 | Prediction of B cell, cytotoxic T lymphocytes, and helper T lymphocytes epitopes

The predicted epitope PTVVNAANVYLKHGGGVAGAL of Nsp3 (236–260), ORF1ab, and ORF1a (1054–1074) of SARS-CoV-2 containing the consensus amino acid sequence for human Parp14 residues among 818–840 and Parp9 residues among 113–134, showed enhanced activation of B-cells by their allergenic nature (Figure 2). BepiPred showed that the epitopes have a large gradient and that the surface of the structure is exposed (Table 2). As mentioned, the predicted epitope of SARS-CoV-2, for CTL and HTL cells shows predicted epitopes with a high antigenic and allergenic property capable of inducing a large autoimmune response once recognized by the MHC Class I and MHC Class II allele numbers (Table 2).

3.3 | Hydrophobic and antigenicity prediction

Hydrophobic and antigenic analyses of SARS-CoV-2 Nsp3 protein and human Parp14/Parp9 for the consensus amino acid sequence are...
# TABLE 1

Preserved epitopes between SARS-CoV-2 Nsp3 and human Parp9 and Parp14

| PUBMED ref     | Protein                        | Epitope                                      | Length       |
|----------------|--------------------------------|----------------------------------------------|--------------|
| XP_011511230.1 | Human PARP14 isoform X1        | VVVNA-N—LKH-GG-A-AL-KA                       | 818–840      |
| NP_001374802.1 | Human PARP9 isoform d          | VVNAAN−L-HGGG-A-AL-KA                       | 113–134      |
| YP_009725295.1 | ORF1α SARS-CoV-2               | PTVVVNAANVYLKHGGGVAGALNKA                     | 1054–1074    |
| YP_009742610.1 | Nsp3 SARS-CoV-2                |                                               | 236–260      |
| YP_009724389.1 | ORF1ab SARS-CoV-2              |                                               | 1054–1074    |

**FIGURE 1**

Basic local alignment showed epitopes of SARS-CoV-2 ORF1α, Nsp3, and ORF1ab with high similarity (in red). Human Parp14 (XP_011511230.1) and Parp9 (NP_001374802.1) showed a 14 aa with great similarity with SARS-CoV-2 ORF1α, Nsp3, and ORF1ab epitopes. Parp14 epitope framed in green and Parp9 epitope framed in blue were selected with prediction of B cell, cytotoxic T lymphocytes, and helper T lymphocytes epitope tools.

**FIGURE 2**

SARS-CoV-2 Nsp3 protein (PDB 6WEY) with consensus sequences with Parp9 in blue (A) and Parp14 in red (B). Human Parp9 (C) and human Parp14 (D) with consensus sequences in red. All epitopes are exposed.
shown in Table 3. This data showed that the amino acids of Nsp3, ORF1ab, and ORF1a from SARS-CoV-2 and from human PARP14 and PARP9 present an area of antigen–antibody complex formation. Amino acids of human PARP14 and PARP9 highlighted in gray even if different than the predicted Nsp3 viral epitope, present good antigenic and hydrophobic properties to form an antigen–antibody complex. This method can determine which portion of a protein will end up in the interior or on the outer side of said protein as a characteristic of most optimal antigenic epitopes is to be flexible, hydrophilic, and lie on the surface of the protein.

3.4 | Prediction of the 3D structures of the predicted epitope and MHC I HLA-A*0201 allele and MHC II HLA-DR52c allele molecular docking

Figure 3 shows the 3D epitope prediction. The sOPEP energy for the predicted epitope VVVNAANVYLKH was −8.54667 kcal/mol; with protein-peptide docking showing an interface between the MHC Class I receptor HLA-A*0201 allele and peptide-binding energy of −17.59 kcal/mol (Figure 4A). The sOPEP energy for the predicted epitope VVNAANVYLKHGGGVA was −9.76096 kcal/mol; with protein-peptide docking showing an interface between the MHC Class I receptor HLA-A*11:01 allele and peptide binding energy of −5.97 kcal/mol (Figure 4B). The sOPEP energy for the predicted epitope PTVVVNAANVYLKHGGVGAGA was −18.5287 kcal/mol; with protein-peptide docking showing an interface between the MHC Class II receptor HLA-DR52c allele and peptide-binding energy of −37.17 kcal/mol (Figure 4C). These results suggest that the predicted epitopes may have a high binding affinity with MHC Class I and MHC Class II and are capable to direct immune response.

4 | DISCUSSION

SARS-CoV-2 is a new and serious infectious disease that affects the entire world, threatening the health and life of the human population. The infection produced by the virus results in a strong immune response that releases large amounts of cytokines and chemokines, a phenomenon known as cytokine storm, exhibiting systemic hyper-inflammation, leading to a high incidence of immune disorders, organ failure, and mortality.11,29,30 This systemic hyper-inflammatory condition is known as MAS that can be associated with SARS-CoV-2 pneumonia and its exacerbation.11,12

MAS can occur in severe infections caused by a wide variety of bacterial, fungal, protozoal, rickettsial, and viral pathogens,31–33 MAS is also found in patients with severe sepsis with a high risk of mortality.31 In patients with severe SARS-CoV-2, the MAS profile related to inflammatory macrophage M1 may be explained, in part, by the systemic cytokine profiles observed in these cases, with increased production of IL-6, IL-7, and TNF-α and inflammatory chemokines such as CCL2, CC13, and CXCL10.36 However, the amounts of IL-1β serum levels were not increased in SARS-CoV-2 patients, which could indicate the absence of the inflammasome activation.36 Other characteristics found in a typical MAS profile, such as hypercytokinemia, elevated amounts of serum ferritin, CRP, and dimer levels are the same as those found in patients with SARS-CoV-2 pneumonia.36

The polarization of macrophages is crucial to whether their function is pro-inflammatory (M1) or anti-inflammatory (M2). The M1 phenotype is activated by IFN-γ, TNF-α, IL-1, IL-6, IL-12, IL-23, and LPS to produce an inflammatory response.37 On the other hand, cytokines IL-4 and IL-13 produce stimulation and differentiation of the M2 phenotype that promotes resolution of inflammation and wound healing.37 PARP14 contributes to an IL-4-induced gene expression, as a co-activator, through interaction with cytokine-induced signal transducers and activators of transcription 6 (STAT6).17,38 PARP14 is important for the differentiation of naive T helper (Th) cells to a Th2 phenotype that produces IL-4, IL-5, and IL-13, and is as well responsible for the polarization of the macrophages towards the M2 macrophages phenotype.17 Thus, PARP14 deficiency accelerates the activation of M1 macrophages leading to an inflammatory state.17 On the other hand, PARP9 is an important molecule that provides protection against lethal viral infections through interferon responses,39 and as PARP14, also participates in the polarization of macrophages towards the M2 phenotype.17

| TABLE 2  | MHC-I and MHC-II alleles prediction epitopes |
|-----------|---------------------------------------------|
| S/N | Core peptide | Length | MHCI alleles | MHCII alleles | Score/percentile | Antigenicity | Toxicity | Allergenicity |
| 1 | VVVNAANVYLKH | 12 | HLA-B*15:01 |  | 0.752031 | 0.7077 | Nontoxic | Allergen |
|  |  |  | HLA-A*30:02 |  | 0.529167 |  |  |  |
|  |  |  | HLA-B*35:01 |  | 0.5167 |  |  |  |
| 2 | VVNAANVYLKHGGGVA | 16 | HLA-A*11:01 |  | 0.680557 | 0.6447 | Nontoxic | Allergen |
|  |  |  | HLA-A*03:01 |  | 0.544704 |  |  |  |
| 3 | PTVVVNAANVYLKHGGGVAGA | 21 | HLA-DRB1*13:02 |  | 0.33 | 0.5285 | Nontoxic | Allergen |
|  |  |  | HLA-DRB1*13:02 |  | 0.59 |  |  |  |
| SARS-CoV-2 Nsp3 Residue | Position | Hydrophobicity | Antigenic | Human Parp9 Residue | Position | Hydrophobicity | Antigenic | Human Parp14 Residue | Position | Hydrophobicity | Antigenic |
|-------------------------|----------|----------------|------------|---------------------|----------|----------------|------------|---------------------|----------|----------------|------------|
| Pro                     | 236      | -0.31          | 0.45       |                     |          |                |            |                     |          |                |            |
| Thr                     | 237      | -0.36          | -0.45      |                     |          |                |            |                     |          |                |            |
| Val                     | 238      | -0.99          | -0.3       |                     |          |                |            |                     |          |                |            |
| Val                     | 239      | -0.72          | -0.6       | Val                 | 113      | -1.42          | -0.3       | Val                 | 818      | -1.53          | -0.6      |
| Val                     | 240      | -0.77          | -0.6       | Val                 | 114      | -0.83          | -0.3       | Val                 | 819      | -1.02          | -0.6      |
| Asn                     | 241      | -1.41          | -0.6       | Asn                 | 115      | 0.02           | -0.6       | Asn                 | 821      | 0.04           | -0.2      |
| Ala                     | 242      | -1.34          | -0.6       | Ala                 | 116      | 0.02           | -0.3       | Ala                 | 822      | 0.04           | 1         |
| Ala                     | 243      | -1.3           | -0.6       | Ala                 | 117      | -0.2           | 0.75       | Ser                 | 823      | 0.09           | 1.3       |
| Asn                     | 244      | -0.4           | -0.6       | Asn                 | 118      | -0.16          | 0.75       | Asn                 | 824      | 0.99           | 1.3       |
| Val                     | 245      | 0.42           | -0.6       | Glu                 | 119      | 0.67           | 0.45       | Glu                 | 825      | 1.81           | 0.9       |
| Tyr                     | 246      | 0.08           | -0.6       | Asp                 | 120      | 0.32           | 0.45       | Asp                 | 826      | 1.57           | 0.9       |
| Leu                     | 247      | 0.32           | -0.6       | Leu                 | 121      | 0.57           | 0.45       | Leu                 | 827      | 1.81           | 0.9       |
| Lys                     | 248      | 0.57           | -0.6       | Leu                 | 122      | 0.81           | 0.3        | Lys                 | 828      | 1.77           | 0.9       |
| His                     | 249      | -0.29          | 0.25       | His                 | 123      | 0              | 0.25       | His                 | 829      | 0.96           | 0.7       |
| Gly                     | 250      | -0.02          | 0.65       | Gly                 | 124      | -0.59          | -0.05      |                    |          |                |            |
| Gly                     | 251      | -0.12          | 0.85       | Gly                 | 125      | -1.4           | -0.05      |                    |          |                |            |
| Gly                     | 252      | 0.1            | 0.25       | Gly                 | 126      | -1.18          | -0.05      |                    |          |                |            |
| Val                     | 253      | -0.76          | -0.3       | Leu                 | 127      | -1.18          | -0.6       |                    |          |                |            |
| Ala                     | 254      | -0.72          | -0.6       | Ala                 | 128      | -2             | -0.6       |                    |          |                |            |
| Gly                     | 255      | -0.33          | -0.6       |                    |          |                |            |                    |          |                |            |
| Ala                     | 256      | -0.58          | -0.3       |                    |          |                |            |                    |          |                |            |
FIGURE 3  Epitope 3D model for VVVNAANVYLKH (A) against Parp14, VVNAANVYLKHGGGVA against Parp9 (B), and PTVVVNAANVYLKHGGGVAGA (C) against both Parp14/Parp9, was representative of the best clusters

FIGURE 4  Molecular docking of the peptide: (A) Parp14 VVVNAANVYLKH epitope with MHC Class I HLA-A*02:01 allele had binding free of $-17.59$ kcal/mol. (B) Parp9 VVNAANVYLKHGGGVA epitope with MHC Class I HLA-A*02:01 allele had binding free of $-5.97$ kcal/mol. (C) Parp14/Parp9 epitope PTVVVNAANVYLKHGGGVAGA with MHC Class II HLA-DR52c allele had binding free of $-37.17$ kcal/mol
This in silico study showed that the SARS-CoV-2 Nsp3 protein, is critical for the virus replication in cells, and/or ORF1ab and has similarity to human PARP14 and PARP9. Thus, PARP14 could be depressed by a phenomenon of molecular mimicry causing the polarization of the M1 macrophage phenotype triggering the SARS-CoV-2 related cytokine storm by a hyper-inflammatory state as well as the MAS. In this manner, this study demonstrated that PARP9 could be depressed by the same phenomenon causing anti-inflammatory macrophage depletion and poor interferon signaling leading to weak host defense against viral infections. The hypothesis of this study is as follows: when SARS-CoV-2 enters the body, macrophages and infected cells activate an early immune response through TLRs (TLR4, TLR3, and TLR7) triggering the expression of pro-inflammatory cytokines and Type I/II interferon genes. B-1 cells, belonging to innate immunity, through MHC Class I, can recognize viral epitopes and produce natural IgM against SARS-CoV-19, furthermore, the study of the activation of immunity from MHC Class I allowed us to observe the possible aggressiveness of SARS-CoV-2 by mounting a CD8+ immune response. These CD8+ cells under unknown conditions may act as Tc-APCs that can activate an antiviral immune response by presenting viral peptides to other specialized cells. On another hand, as the cells mainly present as macrophages, the viral epitope via MHC Class II may be present to enhance the production of selective antibodies against PARP14/PARP9 causing an alteration in the immune regulation, allowing the polarization and activation of the M1 macrophage phenotype leading to the hyper-inflammatory state related to SARS-CoV-2. Inflammatory macrophages mainly release IL-6, which is responsible for the SARS-CoV-2 related macrophtage activation syndrome, however, the presence of this cytokine produces the decrease of NK and CD8+ T cells, a condition found in patients with severe SARS-CoV-2 infections. This scenario produces in the SARS-CoV-2 patient a state of constant hyper-inflammation, without macrophtage immune regulation. The combination of the decrease of PARP14/PARP9 responsible for the polarization of anti-inflammatory macrophages (M2) and a weak host’s viral response due to the decrease of NK and CD8+ cells will lead to a fatal outcome for the patient.

The results of this study are in agreement with previous studies denoting the presence of molecular mimicry in SARS-CoV-2 between PARP14/PARP9 and the viral proteome and its importance in the SARS-CoV-2 infection.

5 | CONCLUSION

Within the limits of this study, it can be assumed that, in patients with severe SARS-CoV-2 infections, a molecular mimicry phenomenon of human PARP14 and PARP9 may be present leading to a hyperinflammatory state due to the macrophage activation syndrome known as cytokine storm-related to SARS-CoV-2.

ACKNOWLEDGMENTS

The author thanks Miguel Chavez Fumagalli for the extensive review of this study. This study is supported by Vicerrectorado de Investigación of Universidad Católica de Santa María, Arequipa, Perú.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

ORCID

Gustavo Obando-Pereda http://orcid.org/0000-0001-6044-1551

REFERENCES

1. Claverie JM. A putative role of de-mono-ADP-ribosylation of STAT1 by the SARS-CoV-2 Nsp3 protein in the cytokine storm syndrome of COVID-19. Viruses. 2020;12(6).
2. Nasrghandi A, Allameh SF, Safarpour R. All about COVID-19 in brief. New Microbes New Infect. 2020;35:100678.
3. Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020;34(2):75-80.
4. The Lancet Infectious Diseases. Challenges of coronavirus disease 2019. Lancet Infect Dis. 2020;20(9):261.
5. WHO. Coronavirus Disease (COVID-19) Situation Reports. 2021; https://covid19.who.int/. Accessed March 21, 2021.
6. Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med. 2020;28(2):174-184.
7. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLOS Pathog. 2020;16(6):e1008536.
8. Grenga L, Armengaud J. Proteomics in the COVID-19 battlefield: first semester check-up. Proteomics. 2020;21:e2000198.
9. Kumar A, Prasoon P, Kumari C, et al. SARS-CoV-2-specific virulence factors in COVID-19. J Med Viral. 2020;93:1343-1350.
10. Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, Ji Macario A, Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev. 2020;19(8):102591.
11. Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19. Inflamm Regen. 2020;40:19.
12. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytosine-rich single-stranded DNA in the pathogenesis of autoimmune disease. Autoimmun Rev. 2016;15(12):1080-1088.
13. Higashi H, Maejima T, Lee LH, et al. A study into the ADP-ribosylome of IFN-γ and IFN-α stimulated THP-1 cells identifies ARTD8/PARP14 and ARTD9/PARP9 ADP-ribosyltransferase. J Proteome Res. 2019;18(4):1607-1612.
14. Qin W, Wu HJ, Cao LQ, et al. Research progress on PARP14 as a potential target for cancer treatment. Life Sci. 2020;251:117391.
15. Gruenwald ME, Chen Y, Kuny C, et al. The coronavirus macro-domain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression. PLOS Pathog. 2019;15(5):e1007756.
16. Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010;35(4):208-219.
17. Iwata H, Goetsch C, Sharma A, et al. PARP9 and PARP14 cross-regulate macrophage activation via STAT1-ADP-ribosylation. Nat Commun. 2016;7:12847.
18. Webb TE, Saad R. Sequence homology between human PARP14 and the SARS-CoV-2 ADP ribose 1’-phosphatase. Immuno Lett. 2020;224:38-39.
19. Obando-Pereda GA. GAKG-RGEKG an epitope that provokes immune cross-reactivity between Prevotella sp. and human collagen.
20. Sievers F, Higgins DG. Clustal Omega for making accurate alignments of many protein sequences. *Protein Sci Publ Protein Soc*. 2018;27(1):135-145.

21. Dhanda SK, Mahajan S, Paul S, et al. IEDB-AR: immune epitope database-analysis resource in 2019. *Nucleic Acids Res*. 2019;47(W1):W502-W506.

22. Xie Q, He X, Yang F, et al. Analysis of the genome sequence and prediction of B-Cell epitopes of the envelope protein of Middle East respiratory syndrome-coronavirus. *IEEE/ACM Trans Comput Biol Bioinf*. 2018;15(4):1344-1350.

23. Yang J, Zhang Y. Protein structure and function prediction using I-TASSER. *Curr Protoc Bioinform*. 2015;52:5.8.1-5.8.15.

24. Shen Y, Maupetit J, Derreumaux P, Tuffery P. Improved PEP-FOLD approach for peptide and miniprotein structure prediction. *J Chem Theory Comput*. 2014;10(10):4745-4758.

25. Rigo MM, Antunes DA, Vaz de Freitas M, et al. DockTope: a web-based tool for automated pMHC-I modelling. *Sci Rep*. 2015;5:18413.

26. Kurcinski M, Badaczewska-Dawid A, Kolinski M, Kolinski A, Kmiecik S. Flexible docking of peptides to proteins using CABS-dock. *Protein Sci Publ Protein Soc*. 2020;29(1):211-222.

27. Feng T, Chen F, Kang Y, et al. HawkRank: a new scoring function for protein-protein docking based on weighted energy terms. *J Cheminf*. 2017;9(1):66.

28. Jiang Y, Wei X, Guan J, et al. COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential. *Clin Immunol*. 2020;218:108516.

29. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol*. 2017;39(5):529-539.

30. Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J Infect Dis*. 2020;221(11):1762-1769.

31. Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. *BLOOD*. 2011;118(17):4577-4584.

32. Cascio A, Pernice LM, Barberi G, et al. Secondary hemophagocytic lymphohistiocytosis in zoonoses. A systematic review. *Eur Rev Med Pharmacol Sci*. 2012;16(10):1324-1337.

33. Maakaronu NR, Moanna A, Jacob JT, Albrecht H. Viral infections associated with haemophagocytic syndrome. *Rev Med Virol*. 2010;20(2):93-105.

34. Schulert GS, Cron RQ. The genetics of macrophage activation syndrome. *Genes Immun*. 2020;21(3):169-181.

35. Sica A, Colombo MP, Trama A, Horn L, Garassino MC, Torri V. Immunometabolic status of COVID-19 cancer patients. *Physiol Rev*. 2020;100(4):1839-1850.

36. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol*. 2020;20(6):355-362.

37. Funes SC, Rios M, Escober-Vara J, Kalergis AM. Implications of macrophage polarization in autoimmunity. *Immunology*. 2018;154(2):186-195.

38. Mehrotra P, Riley JP, Patel R, Li F, Voss L, Goenka S. PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation. *J Biol Chem*. 2011;286(3):1767-1776.

39. Zhang Y, Mao D, Roswit WT, et al. PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection. *Nature Immunol*. 2015;16(12):1215-1227.

40. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-2019: the role of the Nsp2 and Nsp3 in its pathogenesis. *J Med Virol*. 2020;92(6):584-588.

41. Soliman MS, AbdelFattah M, Aman SMN, Ibrahim LM, Aziz RK. A gapless, unambiguous RNA metagenome-assembled genome sequence of a unique SARS-CoV-2 variant encoding spike S813I and ORF1a A859V substitutions. *OMICS J Integr Biol*. 2021;25(2):123-128.

42. da Silva SJR, Alves da Silva CT, Mendes RPG, Pena L. Role of non-structural proteins in the pathogenesis of SARS-CoV-2. *J Med Virol*. 2020;92(9):1427-1429.

43. Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. *Open Biol*. 2020;10(9):200160.

44. Aziz M, Brenner M, Wang P. Therapeutic potential of B-1a cells in COVID-19. *Shock*. 2020;54(5):586-594.

45. La Porta CAM, Zapperi S. Estimating the binding of Sars-CoV-2 peptides to HLA class I in human subpopulations using artificial neural networks. *Cell Syst*. 2020;11(4):412-417.

46. Xiao D, Hao S, Xiang J. CD8+ cytotoxic T-cell responses via acquired peptide complexes and CD80 costimulation, and IL-2 secretion. *J Immunol*. 2006;177(5):2976-2984.

47. Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. *Front Immunol*. 2019;10:119.

48. Masselli E, Vaccarezza M, Carubbi C, et al. NK cells: a double edge sword against SARS-CoV-2. *Adv Biol Regul*. 2020;77:100737.

49. Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. *Physiol Res*. 2020;69(3):379-388.

50. Tauber AL, Schweiker SS, Levonis SM. The potential association between PARP14 and the SARS-CoV-2 infection (COVID-19). *Future Med Chem*. 2021;13:587-592.

---

How to cite this article: Obando-Pereda G. Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach. J Med Virol. 2021;93:5350–5357. https://doi.org/10.1002/jmv.27040